Vericel EV/EBIT VCEL

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2021.

Today, Oct 23, 2026: 116×
5-year median: 240×
Against its 5-year history: 18th; percentile: 0 is its lowest day, 100 its highest
5-year range: 104× to 498×
Peer median: 17.8×

Vericel's EV/EBIT is 116× as of Oct 23, 2026.

That is below its 5-year median of 240×, lower than on 82% of days in the last 5 years.

Over that time it ranged from 104× in May 2026 to 498× in Mar 2025.

The median for 8 biotech stocks of a similar size is 17.8×.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	116×	104×	269×
2025	263×	251×	498×
2024	n/m a value too high to mean anything
2023	n/m a value too high to mean anything
2022	n/m a value too high to mean anything
2021	240×	240×	295×

Against its peers

Companies in Biotechnology nearest Vericel's size, closest first, today.

Company	EV/EBIT
VCELVericel	116×
ADMAAdma Biologics	10.9×
MGTXMeiraGTx	4.6×
KRYSKrystal Biotech	42.4×
RGENRepligen	160×
TECHBIO-TECHNE	44.9×
HALOHalozyme Therapeutics	17.4×
NBIXNeurocrine Biosciences	18.2×
EXELExelixis	15.4×
Peer median	17.8×

Where Vericel ranks

#16of 17Biotech stocks with the lowest EV/EBIT

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Vericel

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.